Cargando…
Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study
OBJECTIVES: Australian guidelines recommend all adults aged 50–70 years old without existing contraindications consider taking low-dose aspirin (100–300 mg per day) for at least 2.5 years to reduce their risk of developing colorectal cancer. We aimed to explore clinicians’ practices, knowledge, opin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925937/ https://www.ncbi.nlm.nih.gov/pubmed/33550247 http://dx.doi.org/10.1136/bmjopen-2020-042261 |
_version_ | 1783659361209417728 |
---|---|
author | Milton, Shakira McIntosh, Jennifer Yogaparan, Thivagar Alphonse, Pavithran Saya, Sibel Karnchanachari, Napin Nguyen, Peter Lau, Phyllis Macrae, Finlay Emery, Jon |
author_facet | Milton, Shakira McIntosh, Jennifer Yogaparan, Thivagar Alphonse, Pavithran Saya, Sibel Karnchanachari, Napin Nguyen, Peter Lau, Phyllis Macrae, Finlay Emery, Jon |
author_sort | Milton, Shakira |
collection | PubMed |
description | OBJECTIVES: Australian guidelines recommend all adults aged 50–70 years old without existing contraindications consider taking low-dose aspirin (100–300 mg per day) for at least 2.5 years to reduce their risk of developing colorectal cancer. We aimed to explore clinicians’ practices, knowledge, opinions, and barriers and facilitators to the implementation of these new guidelines. METHODS: Semistructured interviews were conducted with clinicians to whom the new guidelines may be applicable (Familial Cancer Clinic staff (geneticists, oncologists and genetic counsellors), gastroenterologists, pharmacists and general practitioners (GPs)). The Consolidated Framework for Implementation Research (CFIR) underpinned the development of the interview guide. Coding was inductive and themes were developed through consensus between the authors. Emerging themes were mapped onto the CFIR domains: characteristics of the intervention, outer setting, inner setting, individual characteristics and process. RESULTS: Sixty-four interviews were completed between March and October 2019. Aspirin was viewed as a safe and cheap option for cancer prevention. GPs were considered by all clinicians as the most important health professionals for implementation of the guidelines. Cancer Council Australia, as a trusted organisation, was an important facilitator to guideline adoption. Uncertainty about aspirin dosage and perceived strength of the evidence, precise wording of the recommendation, previous changes to guidelines about aspirin and conflicting findings from trials in older populations were barriers to implementation. CONCLUSION: Widespread adoption of these new guidelines could be an important strategy to reduce the incidence of bowel cancer, but this will require more active implementation strategies focused on primary care and the wider community. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12620001003965). |
format | Online Article Text |
id | pubmed-7925937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-79259372021-03-19 Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study Milton, Shakira McIntosh, Jennifer Yogaparan, Thivagar Alphonse, Pavithran Saya, Sibel Karnchanachari, Napin Nguyen, Peter Lau, Phyllis Macrae, Finlay Emery, Jon BMJ Open Qualitative Research OBJECTIVES: Australian guidelines recommend all adults aged 50–70 years old without existing contraindications consider taking low-dose aspirin (100–300 mg per day) for at least 2.5 years to reduce their risk of developing colorectal cancer. We aimed to explore clinicians’ practices, knowledge, opinions, and barriers and facilitators to the implementation of these new guidelines. METHODS: Semistructured interviews were conducted with clinicians to whom the new guidelines may be applicable (Familial Cancer Clinic staff (geneticists, oncologists and genetic counsellors), gastroenterologists, pharmacists and general practitioners (GPs)). The Consolidated Framework for Implementation Research (CFIR) underpinned the development of the interview guide. Coding was inductive and themes were developed through consensus between the authors. Emerging themes were mapped onto the CFIR domains: characteristics of the intervention, outer setting, inner setting, individual characteristics and process. RESULTS: Sixty-four interviews were completed between March and October 2019. Aspirin was viewed as a safe and cheap option for cancer prevention. GPs were considered by all clinicians as the most important health professionals for implementation of the guidelines. Cancer Council Australia, as a trusted organisation, was an important facilitator to guideline adoption. Uncertainty about aspirin dosage and perceived strength of the evidence, precise wording of the recommendation, previous changes to guidelines about aspirin and conflicting findings from trials in older populations were barriers to implementation. CONCLUSION: Widespread adoption of these new guidelines could be an important strategy to reduce the incidence of bowel cancer, but this will require more active implementation strategies focused on primary care and the wider community. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12620001003965). BMJ Publishing Group 2021-02-05 /pmc/articles/PMC7925937/ /pubmed/33550247 http://dx.doi.org/10.1136/bmjopen-2020-042261 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Qualitative Research Milton, Shakira McIntosh, Jennifer Yogaparan, Thivagar Alphonse, Pavithran Saya, Sibel Karnchanachari, Napin Nguyen, Peter Lau, Phyllis Macrae, Finlay Emery, Jon Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study |
title | Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study |
title_full | Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study |
title_fullStr | Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study |
title_full_unstemmed | Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study |
title_short | Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study |
title_sort | clinicians’ opinions on recommending aspirin to prevent colorectal cancer to australians aged 50–70 years: a qualitative study |
topic | Qualitative Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925937/ https://www.ncbi.nlm.nih.gov/pubmed/33550247 http://dx.doi.org/10.1136/bmjopen-2020-042261 |
work_keys_str_mv | AT miltonshakira cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT mcintoshjennifer cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT yogaparanthivagar cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT alphonsepavithran cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT sayasibel cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT karnchanacharinapin cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT nguyenpeter cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT lauphyllis cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT macraefinlay cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy AT emeryjon cliniciansopinionsonrecommendingaspirintopreventcolorectalcancertoaustraliansaged5070yearsaqualitativestudy |